NCT00104429终止2 期
A PhaseIIb, 96 Week, Randomised, Partially Double-blinded, Multicentre, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, PK and Antiviral Effect of GW873140 in Combination With COMBIVIR (Lamivudine and Zidovudine) Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy Naive Adults
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 125
- 试验地点
- 51
- 主要终点
- Proportion of subjects with viral loads <400 copies/mL remaining on randomized treatment through Week 12
研究概览
简要总结
This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Combivir in HIV infected, untreated subjects.
详细描述
A Phase IIb, 96 week, randomized, partially double-blinded, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW873140 in combination with Combivir (lamivudine and zidovudine) upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naive adults
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV infected subjects.
- •Females must be of either non-childbearing age, or have a negative pregnancy test.
- •All subjects participating in this study should be counseled on the practice of safe sex using a proven double barrier method of contraception throughout the study.
- •Screening lab result of plasma HIV-1 RNA greater than or equal to 10,000 copies/mL and CD4 cell count greater than or equal to 100 cells/mm
- •Have CC Chemokine Receptor5-tropic (R5-tropic) virus based on viral tropism test at screening visit.
- •Have no drug resistance mutations in HIV-1 Reverse Transcriptase based on resistance test at screening visit.
- •Be treatment-naive, defined as less than or equal to 2 weeks of treatment with a protease inhibitor (PI) or a nucleoside reverse transcriptase inhibitor/nucleotide reverse transcriptase inhibitor (NRTI/ NtRTI), or less than or equal to 7 days of therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI).
- •Prior treatment with any entry inhibitor, attachment inhibitor, or fusion inhibitor (experimental or approved) is not allowed.
- •Be able to understand and follow with protocol requirements, instructions and protocol-stated restrictions.
- •Signed and dated written informed consent prior to study entry.
排除标准
- •Detection of any CXC Receptor4-tropic (X4-tropic) virus, based on viral tropism test at screening.
- •Any drug resistance mutations in HIV-1 Reverse Transcriptase based on resistance test at screening visit.
- •Active Class C AIDS-defining illness.
- •Laboratory abnormalities at screen.
- •Significant blood loss prior to study start.
- •Pregnant or breastfeeding women.
- •Additional qualifying criteria to be determined by the physician.
结局指标
主要结局
Proportion of subjects with viral loads <400 copies/mL remaining on randomized treatment through Week 12
次要结局
- - Comparison of safety and tolerability of different dosage regimens of GW873140 plus Combivir to standard of care regimen. - Assessment of drug resistance over time. - Co-receptor tropism following virological failure.
研究者
研究点 (51)
Loading locations...
相似试验
终止
2 期
GW873140 In Combination With Kaletra In HIV Infected SubjectsHIV InfectionInfection, Human Immunodeficiency Virus INCT00102778ViiV Healthcare175
已完成
2 期
Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)Depressive Disorder, MajorNCT00413023GlaxoSmithKline348
已完成
1 期
Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy VolunteersIrritable ColonIrritable Bowel Syndrome (IBS)NCT00376896GlaxoSmithKline25
已完成
2 期
GW873140 to Treat HIV-1 Infected AdultsHIV InfectionsNCT00076284National Institute of Allergy and Infectious Diseases (NIAID)20
已完成
1 期
Phase I Study of GW642444M in Healthy Japanese Male SubjectsPulmonary Disease, Chronic ObstructiveNCT00964249GlaxoSmithKline32